@article{396b2bba9923429d8b949b97c7d31da1,
title = "IGHV4-39 deletion polymorphism does not associate with risk or outcome of multiple sclerosis",
abstract = "The restricted use of immunoglobulin heavy chain variable (IGHV) family 4 gene segments by clonally expanded B cells in brain lesions and cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients is well documented. Specifically, the overrepresentation of gene IGHV4-39 has been highlighted in multiple studies. To investigate the role of IGHV4-39 in MS, we screened 193 MS cases, representing the extremes of clinical outcome (benign and malignant), and 187 controls for a previously reported germline deletion polymorphism containing IGHV4-39. We did not reveal a genetic association linking this polymorphism to MS risk or progression.",
keywords = "CNV, IGHV4-39, Immunoglobulin, Multiple sclerosis",
author = "Watson, {Corey T.} and Ramagopalan, {Sreeram V.} and Morrison, {Katie M.} and Ebers, {George C.} and Felix Breden",
note = "Funding Information: This study was funded by the Natural Sciences and Engineering Research Council of Canada and the SFU UILO Prototype Development Fund . SVR is funded by the Medical Research Council of the United Kingdom . GCE is the Action Research Professor of Clinical Neurology at the University of Oxford. The authors would like to thank all patients who generously participated in this study and physicians participating in the CCPGSMS. Additionally, the authors thank Nazila Taheri for assistance with PCR. Experiments performed for this investigation comply with current guidelines and ethics.",
year = "2010",
month = aug,
doi = "10.1016/j.jneuroim.2010.04.012",
language = "English",
volume = "225",
pages = "164--166",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",
}